Latest Breaking News On - Enanta pharmaceuticals inc - Page 19 : comparemela.com

Enanta Pharma (ENTA) Reports Positive Data From a Phase 1 Clinical Study of EDP-323

Enanta Pharma (ENTA) Reports Positive Data From a Phase 1 Clinical Study of EDP-323
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesScottt rottinghausJennifer vieraEnanta pharmaceuticals incCenters for disease control preventionExchange commissionEnanta pharmaceuticalsDrug administrationCenters for diseaseFast trackSenior vice presidentChief medical officerDisease controlRespiratory syncytial virusYoung children

Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

- Generally Safe and Well-Tolerated up to 800 mg for Seven Days with Pharmacokinetics Supportive of Once-Daily Dosing - All Doses Resulted in Strong Exposure Multiples Against Both RSV A and B. | June 20, 2023

United statesScottt rottinghausEnanta pharmaceuticals incDrug administrationExchange commissionEnanta pharmaceuticalsCenters for diseaseFast trackSenior vice presidentChief medical officerDisease control

Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial

Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.

Drug administrationEnanta pharmaceuticals incEnanta pharmaceuticals

Tang Capital Management LLC Acquires 62,300 Shares of Enanta Pharmaceuticals, Inc (NASDAQ:ENTA)

Tang Capital Management LLC raised its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) by 45.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 200,000 shares of the biotechnology company’s stock after purchasing an additional 62,300 shares during the […]

Tang capital managementNews ratings for enanta pharmaceuticals dailyInsider activity at enanta pharmaceuticalsMan groupEnanta pharmaceuticalsExchange commissionAlps advisors incMillennium managementEnanta pharmaceuticals incEnanta pharmaceuticals stock performanceRoyal bankGroup plcNorges bankQuarter for enanta pharmaceuticalsEnanta pharmaceuticals profileGet rating

Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress 2023

07.06.2023 - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that preclinical data from Enanta’s out-licensing portfolio has been accepted for a .

Lang schwarzManuel roqueta riveraInternational liver congressEnanta pharmaceuticals incEnanta pharmaceuticals stockPoster titleMouse modelAbstract identifierEnanta pharmaceuticals